New diagnostic options in hypertrophic cardiomyopathy

American Heart Journal

Volumn 132, Issue 5, 1996, Pages 1031-1041

  Posma, Jan L ^a   Van Der Wall, Ernst E ^b   Blanksma, Paul K ^a   Van Der Wall, Evert ^a   Lie, Kong I ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SUDDEN DEATH;

EID: 0029834076     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90018-6     Document Type: Article

References (148)

1. Wigle ED. Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. Curr Opin Cardiol 1995;10:299-305.
2. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. clinical spectrum and treatment. Circulation 1995; 92:1680-92.
3. Vulpian A. Contribution à l'étude des rétrécissements de l'orifice ventriculo-aortique. Archives de Physiologie 1868;3:456-7.
4. Hallopeau L. Rétrécissement ventriculo-aortique. Gaz Med Paris 1869;24:683-4.
5. Liouville H. Rétrécissement cardiaque sous aortique. Gaz Med Paris 1869;24:161-3.
6. Schminke A. Ueber linksseitige muskulose conusstenosen. Dtsch Med Wochenschr 1907;33:2082-5.
7. Evans W. Familial cardiomegaly. Br Heart J 1949;11:68-82.
8. Brigden W. Uncommon myocardial disease, the noncoronary cardiomyopathies. Lancet 1957;2:1179-84.
9. Brigden W. Hypertrophic cardiomyopathy [editorial]. Br Heart J 1987;58:299-302.
10. Brock RC. Functional obstruction of the left ventricle. Guys Hosp Rep 1957;106:221-38.
11. Teare RD. Asymmetric hypertrophy of the heart in young adults. Br Heart J 1958;20:1-8.
12. Watkins H, Seidman CE, MacRae C, Seidman JG, McKenna W. Progress in familial hypertrophic cardiomyopathy: molecular genetic analyses in the original family studied by Teare. Br Heart J 1992; 67:34-8.
13. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979;43:1242-4.
14. WHO/ISFC Task Force. Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 1980;44: 672-3.
15. Goodwin JF, Oakley CM. The cardiomyopathies. Br Heart J 1972;34:545-52.
16. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy - a review. Prog Cardiovasc Dis 1985;28:1-83.
17. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979;59:689-706.
18. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: recent observations regarding the specificity of three hallmarks of the disease - asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am J Cardiol 1980; 45:141-54.
19. Becker AE. The cardiomyopathies revisited from jungle to jumble. In: Crijns HJGM, Kingma JH, Viersma JW, editors. Heart failure: from conduction to contraction. Dordrecht: Kluwer Academic Publishers, 1994:117-30.
20. Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 1992;70:1333-40.
21. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophie cardiomyopathy. Circulation 1995;92:1336-47.
22. Roberts R, Marian AJ, Bachinski LL. Overview: application of molecular biology to medical genetics. In: Markwald RR, Clark EB, Takao A, editors. Inborn heart disease: developmental mechanisms. Mount Kisco (NY): Futura Press, 1994:87-111.
23. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the β-myosin heavy chain gene: a 908 leu-val mutation and a 403 arg-gln mutation. Circulation 1992;86:345-52.
24. Watkins H, Rosenzweig A, Hwang D-S, Levi T, McKenna W, Seidman CE, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992:326:1108-14.
25. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy: insights provided by comparisons of kindreds with distinct and identical β-myosin heavy chain gene mutations. Circulation 1994;89:22-32.
26. Schwartz K, Carrier L, Guineney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation 1995;91:532-40.
27. Davies MJ, Krikler DM. Genetic investigation and counselling of families with hypertrophic cardiomyopathy. Br Heart J 1994;72:99-101.
28. Lechin M, Quiand left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995;92:1808-12.
29. Yoneya K, Okamoto H, Machida M, Onozuka H, Noguchi M, Mikami T, et al. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1995; 130:1089-93.
30. Hartmann A, Pütz A, Hopf R. Effect of long-term ACE-inhibitor therapy in hypertrophic cardiomyopathy [abstract]. J Am Coll Cardiol 1995;24:234A.
31. Strauer BE. Myocardial oxygen consumption in chronic heart disease: role of wall stress, hypertrophy and coronary reserve. Am J Cardiol 1979;44:730-40.
32. Hirota Y, Furubayashi K, Kiyotaka K, Simizu G, Kino M, Kawamura K, et al. Hypertrophic nonobstructive cardiomyopathy: a precise assessment of hemodynamic characteristics and clinical implications. Am J Cardiol 1982;50:990-7.
33. Pouleur H, Rousseau MF, Van Eyll C, Brasseur LA, Charlier AA. Force-velocity-length relations in hypertrophic cardiomyopathy: evidence of normal or depressed myocardial contractility. Am J Cardiol 1983;52:813-7.
34. Blanksma PK. Pressure-volume and stress-strain relationships in hypertrophic cardiomyopathy. In: Van der Wall E, Lie KI, editors. Recent views on hypertrophic cardiomyopathy. Dordrecht: Martinus Nijhoff, 1985:53-69.
35. Nishi H, Kimura A, Harada H, Koga Y, Adachi K, Matsuyama K, et al. A myosin missense mutation, not a null allele, causes familial hypertrophic cardiomyopathy. Circulation 1995;91:2911-5.
36. Schwartz K. Familial hypertrophic cardiomyopathy: nonsense versus missense mutations. Circulation 1995;91:2865-7.
37. Roberts R. Molecular genetics: therapy or terror? [editorial]. Circulation 1994;89:499-502.
38. Al-Mahdawi S, Chamberlain S, Chojnowska L, Michalak E, Nihoyannopoulos P, Ryan M, et al. The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene. Br Heart J 1994;72:105-11.
39. Ryan MP, ClelandJGF, French JA, Joshi J, Choudhury L, Chojnowska L, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995;76:689-94.
40. McKenna WJ, Stewart JT, Nihoyannopoulos P, McGinty F, Davies MJ. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J 1990;63:287-90.
41. Gregor P, Widimsky P, Cervenka V, Visek V, Hrobonova V. Electrocardiographic changes can precede the development of myocardial hypertrophy in the setting of hypertrophic cardiomyopathy. Int J Cardiol 1989;23:335-41.
42. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. Am J Cardiol 1989;63:1258-65.
43. Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, et al. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1978;58: 402-8.
44. Maron BJ, Wolfson JK, Ciro E, Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 1983;51:189-94.
45. Burch GE, DePasquale NP. Electrocardiogram and spatial vectorcardiogram of localized myocardial hypertrophy. Circulation 1962;26:544-52.
46. Van Dam RT, Roos JP, Durrer D. Electrical activation of ventricles and interventricular septum in hypertrophic obstructive cardiomyopathy. Br Heart J 1972;34:100-12.
47. Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO, Bonow RO, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy: a consecutive analysis in 155 patients. Circulation 1989;80:1259-68.
48. James TN, Marshall TK. De subitaneis mortibus: asymmetrical hypertrophy of the heart. Circulation 1975;51:1149-66.
49. Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol 1979;44:401-12.
50. Alfonso F, Nihoyannopoulos P, Stewart J, Dickie S, Lemery R, McKenna WJ. Clinical significance of giant negative T waves in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:965-71.
51. Moro E, D'Angelo G, Nicolosi GL, Mimo R, Zanuttini D. Long-term evaluation of patients with apical hypertrophic cardiomyopahty: correlation between quantitative echocardiographic assessment of apical hypertrophy and clinical-electrocardiographic findings. Eur Heart J 1995;16:210-7.
52. Maron BJ. The giant negative T wave revisited . . . in hypertrophic cardiomyopathy [editorial]. J Am Coll Cardiol 1990;15:972-3.
53. Lazzeroni E, Domenicucci S, Ten Cate FJ, Varacca A, Zoni A, Francescon P, et al. Electrocardiographic abnormalities in hypertrophic cardiomyopathy: its relation to the extent of myocardial hypertrophy. Am J Noninvasive Cardiol 1988;2:199-204.
54. Lemery R, Kleinebenne A, Nihoyannopoulos P, Aber V, Alfonso F, McKenna WJ. Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol 1990;16:368-74.
55. Saul JP, Arai Y, Berger RD, Lilly LS, Colucci WS, Cohen RJ. Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol 1988;61:1292-9.
56. Woo MA, Moser DK, Stevenson WG. Relationship of heart rate vanability to sudden death in advanced heart failure patients. Circulation 1993;88:1-14.
57. Ajiki K, Murakawa Y, Yanagisawa-Miwa A, Usui M, Yamashita T, Oikawa N, et al. Autonomic nervous system activity in idiopathic dilated cardiomyopathy and in hypertrophic cardiomyopathy. Am J Cardiol 1993;71:1316-20.
58. Counihan PJ, Fei L, Bashir Y, Farrell TG, Haywood GA, McKenna WJ. Assessment of heart rate variability in hypertrophic cardiomyopathy: association with clinical and prognostic features. Circulation 1993;88:1682-90.
59. Fei L, Slade AK, Prasad K, Malik M, McKenna WJ, Camm AJ. Is there increased sympathetic activity in patients with hypertrophie cardiomyopathy? J Am Coll Cardiol 1995;26:472-80.
60. Shimizu M, Sugihara N, Kita Y, Shimizu K, Horita Y, Nakajima K, et al. Long term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J 1992;67:155-60.
61. Simson MB. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 1981;64:235-42.
62. Gavaghan TP, Keely RP, Kuchar DL, Hickie JB, Campbell TJ. The prevalence of arrhythmias in hypertrophic cardiomyopathy: role of ambulatory monitoring and signal-averaged electrocardiography. Aust NZ J Med 1986;16:666-70.
63. Fauchier JP, Cosnay P, Moquet B, Balleh H, Rouesnel PH. Late ventricular potentials and spontaneous and induced ventricular arrhythmias in dilated or hypertrophic cardiomyopathies: a prospective study about 83 patients. PACE Pacing Clin Electrophysiol 1988;11:1974-83.
64. Cripps TR, Counihan PJ, Frenneaux MP, Ward DE, Camm AJ, McKenna WJ. Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:956-61.
65. Kulakowski P, Counihan PJ, Camm AJ, McKenna WJ. The value of time and frequency domain, and spectral temporal mapping analysis of the signal-averaged electrocardiogram in identification of patients with hypertrophic cardiomyopathy at increased risk of sudden death. Eur Heart J 1993;14:941-50.
66. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989;80:1489-92.
67. Saumarez RC, Camm AJ, Panagos A, Gill JS, Stewart JT, De Beider MA, et al. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation 1992;86:467-74.
68. Saumarez RC, Slade AKB, Grace AA, Sadoul N, Camm AJ, McKenna WJ. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy: a prospective study. Circulation 1995;91: 2762-8.
69. Zabel M, Portnoy S, Franz MR. Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 1995;25:746-52.
70. Engler RL, Smith P, LeWinter M, Gosink B, Johnson A. The electrocardiogram in asymmetric septal hypertrophy. Chest 1979;75:167-73.
71. Martin AB, Garson A, Perry JC. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J 1994; 127:64-70.
72. Buja G, Miorelli M, Turrini P, Melachini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993;72:973-6.
73. Hirai M, Hayashi H, Ichihara Y, Adachi M, Kondo K, Suzuki A, et al. Body surface distribution of abnormally low QRST areas in patients with left ventricular hypertrophy; an index of repolarization abnormalities. Circulation 1991;84:1505-15.
74. Dritsas A, Gilligan D, Nihoyannopoulos P, Oakley CM. Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992;36:345-9.
75. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-82.
76. Cui G, Sen L, Sager P, Uppal P, Singh BN. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994;74:896-900.
77. Goldner B, Brandspiegel HZ, Horwitz L, Jadonath R, Cohen TJ. Utility of QT dispersion combined with the signal-averaged electrocardiogram in detecting patients susceptible to ventricular tachyarrhyth-mia. Am J Cardiol 1995;76:1192-4.
78. Fei L, Slade AK, Grace AA, Malik M, Camm AJ, McKenna WJ. Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone. PACE Pacing Clin Electrophysiol 1994;17:2222-7.
79. Solomon SD, Wolff S, Watkins H, Ridker PM, Come P, McKenna WJ, et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol 1993;22:498-505.
80. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995; 26:1699-1708.
81. Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation 1995;92:700-4.
82. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;324:295-301.
83. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in the competitive athlete. J Am Coll Cardiol 1986;7:204-14.
84. Maron BJ, Isner JM, McKenna WJ. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. J Am Coll Cardiol 1994;24:880-4.
85. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596-1601.
86. Spirito P, Pelliccia A, Proschan MA, Granata M, Spataro A, Bellone P, et al. Morphology of the 'athlete's heart' assessed by echocardiography in 947 elite athletes representing 27 sports. Am J Cardiol 1994;74:802-6.
87. Naito J, Masuyama T, Tanouchi J, Mano T, Kondo H, Yamamoto K, et al. Analysis of transmural trend of myocardial integrated ultrasound backscatter for differentiation of hypertrophic cardiomyopathy and ventricular hypertrophy due to hypertension. J Am Coll Cardiol 1994;24:517-24.
88. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992;85:1651-60.
89. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy; significance in producing left ventricular outflow obstruction. Circulation 1991;84:1188-97.
90. Klues HG, Roberts WC, Maron BJ. Morphologic determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 1993;87: 1570-9.
91. McIntosh CL, Maron BJ, Cannon RO, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 1992; 86(Suppl II):II-60-7.
92. Klues HG, Proschan MA, Dollar AL, Spirito P, Roberts WC, Maron BJ. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy: anatomic validation from mitral valve specimen. Circulation 1993;88:548-55.
93. Panza JA, Maron BJ. Simultaneous occurrence of mitral valve prolapse and systolic anterior motion in hypertrophic cardiomyopathy. Am J Cardiol 1991;67:404-10.
94. Petrone RK, Klues HG, Panza JA, Peterson EE, Maron BJ. Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. J Am Coll Cardiol 1992;20:55-61.
95. Zhu W-X, Oh JK, Kopecky SL, Schaff HV, Tajik AJ. Mitral regurgitation due to ruptured chordae tendineae in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1992;20:242-7.
96. Seiler G, Jenni R, Vassalli G, Turina M, Hess OM. Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy. Br Heart J 1995;74:508-16.
97. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987;59:123-9.
98. Kawano S, Iida K, Fujieda K, Yukisada K, Magdi ES, Iwasaki Y, et al. Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy. J Am Coll Cardiol 1995;25:687-92.
99. Choudhury L, Guzzetti S, Lefroy DG, Nihoyannopoulos P, McKenna WJ, Oakley CM, et al. Myocardial β adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 1996;75:50-4.
100. Tomochika Y, Tanaka N, Wasaki Y, Shimizu H, Hiro J, Takahashi T, et al. Assessment of flow profile of left anterior descending coronary artery in hypertrophic cardiomyopathy by transesophageal pulsed Doppler echocardiography. Am J Cardiol 1993;72:1425-30.
101. Memmola C, Iliceto S, Napoli VF, Cavallari D, Santoro G, Rizzon P. Coronary flow dynamics and reserve assessed by transesophageal echocardiography in obstructive hypertrophic cardiomyopathy. Am J Cardiol 1994;74:1147-51.
102. Lazzeroni E, Rolli A, Aurier E, Botti G. Clinical significance of coronary artery disease in hypertrophic cardiomyopathy. Am J Cardiol 1992;70:499-501.
103. O'Gara PT, Bonow RO, Maron BJ, Damske BA, Van Lingen A, Bacharach SL, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987;76:1214-23.
104. Lazzeroni E, Picano E, Dodi C, Morozzi L, Chiriatti GP, Lu C, et al., on behalf of the Echo-Persantine International Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Dipyridamole echocardiography for diagnosis of coexistent coronary artery disease in hypertrophic cardiomyopathy. Am J Cardiol 1995;75:810-3.
105. Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19:91-9.
106. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:752-6.
107. Sehwammenthal E, Block M, Schwartzkopff B, Lösse B, Borggrefe M, Schulte HD, et al. Prediction of the site and severity of obstruction in hypertrophic cardiomyopathy by color flow mapping and continuous wave Doppler echocardiography. J Am Coll Cardiol 1992;20:964-72.
108. Schwammenthal E, Schwartzkopff B, Block M, Johns J, Lösse B, Engberding R, et al. Doppler echocardiographic assessment of the pressure gradient during bicycle ergometry in hypertrophic cardiomyopathy. Am J Cardiol 1992;69:1623-8.
109. Klues HG, Leuner C, Kuhn H. Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. J Am Coll Cardiol 1992;19:527-33.
110. Goldman ME. Hypertrophic cardiomyopathy and intraoperative echocardiography: too much of a good thing may be dangerous [editorial]. J Am Coll Cardiol 1992;20:53-4.
111. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992;20:42-52.
112. Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;20:1066-72.
113. Mohiaddin RH, Longmore DB. Functional aspects of cardiovascular nuclear magnetic resonance imaging: techniques and application. Circulation 1993;88:264-81.
114. Van der Wall EE, Vliegen HW, De Roos A, Bruschke AVG. Magnetic resonance imaging in coronary artery disease. Circulation 1995;92: 2723-39.
115. Higgins CB, Byrd BF, Stark D, McNamara M, Lanzer P, Lipton MJ, et al. Magnetic resonance imaging in hypertrophic cardiomyopathy. Am J Cardiol 1985;55:1121-6.
116. Park JH, Kim YM, Chung JW, Park YB, Han JK, Han MC. MR imaging of hypertrophic cardiomyopathy. Radiology 1992;185:441-6.
117. Sardanelli F, Molinari G, Petillo A, Ottonello C, Parodi RC, Masperone MA, et al. MRI in hypertrophic cardiomyopathy: a morphofunctional study. J Comput Assist Tomogr 1993;17:862-72.
118. Posma JL, Blanksma PK, Van der Wall EE, Hamer HPM, Mooyaart EL, Lie KI. Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: magnetic resonance imaging versus echocardiography. Am Heart J 1996;132:1020-7.
119. Casolo GC, Trotta P, Rostagno C, Poggesi L, Galanti G, Masotti G, et al. Detection of apical hypertrophic cardiomyopathy by magnetic resonance imaging. Am Heart J 1989;117:468-72.
120. Suzuki J, Watanabe P, Takenaka K, Amano K, Amano W, Igarashi T, et al. New subtype of apical hypertrophic cardiomyopathy identified with nuclear magnetic resonance imaging as an underlying cause of markedly inverted T waves. J Am Coll Cardiol 1993;22:1175-81.
121. Mackey ES, Sandler MP, Campbell RM, Graham TP, Atkinson JB, Price R, et al. Right ventricular myocardial mass quantification with magnetic resonance imaging. Am J Cardiol 1990;65:529-32.
122. Doherty NE, Fujita N, Caputo GR, Higgins CB. Measurement of right ventricular mass in normal and dilated cardiomyopathic ventricles using cine magnetic resonance imaging. Am J Cardiol 1992;69:1223-8.
123. Suzuki J, Sakamoto T, Takenaka K, Kawakubo K, Amano K, Takahashi H, et al. Assessment of the thickness of the right ventricular free wall by magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Br Heart J 1988;60:440-5.
124. Ostrzega E, Maddahi J, Honma H, Crues JV III, Resser KJ, Charuzi Y, et al. Quantification of left ventricular myocardial mass in humans by nuclear magnetic resonance imaging. Am Heart J 1989;117:444-52.
125. Allison JD, Flickinger FW, Wright JC, Falls DG III, Prisant LM, VonDohlen TW, et al. Measurement of left ventricular mass in hypertrophic cardiomyopathy using MRI: comparison with echocardiography. Magn Reson Imaging 1993;11:329-34.
126. Farmer D, Higgins CB, Yee E, Lipton MJ, Wahr D, Ports T. Tissue characterization by magnetic resonance imaging in hypertrophic cardiomyopathy. Am J Cardiol 1985;55:230-2.
127. Suzuki J, Chang J, Caputo GR, Higgins CB. Evaluation of right ventricular early diastolic filling by cine nuclear magnetic resonance imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1991;18:120-6.
128. Scheffknecht BHB, Bonow RO, Dwyer AJ, Maron BJ. Functional assessment of left ventricular ejection dynamics by cine-magnetic resonance imaging in hypertrophic cardiomyopathy. Am J Cardiol 1994;73:981-4.
129. Schwammenthal E, Wichter T, Joachimsen K, Auffermann W, Peters PE, Breithardt G. Detection of regional left ventricular asynchrony in obstructive hypertrophic cardiomyopathy by magnetic resonance imaging. Am Heart J 1994;127:600-6.
130. Maier SE, Fischer SE, McKinnon GC, Hess OM, Krayenbuehl HP, Boesiger P. Evaluation of left ventricular segmental wall motion in hypertrophie cardiomyopathy with myocardial tagging. Circulation 1992;86:1918-26.
131. Kramer CM, Reichek N, Ferrari VA, Theobald T, Dawson J, Axel L. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994;90:186-94.
132. Young AA, Kramer CM, Ferrari VA, Axel L, Reichek N. Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy. Circulation 1994;90:854-67.
133. Dong SJ, MacGregor JH, Crawley AP, McVeigh E, Belenkie I, Smith ER, et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic eardiomyopathy: a three-dimensional tagged magnetic resonance imaging study. Circulation 1994; 90:1200-9.
134. Sayad DE, Willett DL, Bridges WH, Chwialkowski M, McColl R, Payne J, et al. Noninvasive quantitation of left ventricular wall thickening using cine magnetic resonance imaging with myocardial tagging. Am J Cardiol 1995;76:985-9.
135. De Roos A, Doornbos J, Luyten PR, Oosterwaal LJMP, Van der Wall EE, Den Hollander JA. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging 1992;2:711-9.
136. 31P magnetic resonance spectroscopy using the rotating frame-depth selection technique. Ann N Y Acad Sci 1987; 508:321-32.
137. Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, et al. High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies: a study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 1992;56:620-6.
138. 201Tl myocardial perfusion imaging. Am Heart J 1993;125:1323-8.
139. Buser PT, Wagner S, Wu ST, Derugin N, Parmley WW, Higgins CB, et al. Verapamil preserves myocardial performance and energy metabolism in left ventricular hypertrophy following ischemia and reperfusion: phosphorus 31 magnetic resonance spectroscopy study. Circulation 1989;80:1837-45.
140. Niemeyer MG, Kuijper AFM, Gerhards LJ, D'Haene EG, Van der Wall EE. Nitrogen 13 ammonia perfusion imaging: relation to metabolic imaging. Am Heart J 1993;125:848-54.
141. Camici PG. State of the art in cardiac positron emission tomography. In: Van Der Wall EE, Blanksma PK, Niemeyer MG, Paans AMJ, editors. Cardiac positron emission tomography: viability, perfusion, receptors and cardiomyopathy. Dordrecht: Kluwer Academic Publishers, 1995:1-14.
142. Camici P, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G, et al. Coronary vasodilatation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.
143. Gistri R, Cecchi F, Choudhury L, Montereggi A, Sorace O, Salvadori PA, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 1994;74:363-8.
144. Choudhury L, Gistri R, Ryan M, Cecchi F, McKenna WJ, Camici PG. Stress-induced subendocardial underperfusion: a potential mechanism of ischemia in hypertrophic cardiomyopathy [abstract]. J Am Coll Cardiol 1995;26(Suppl A):28A.
145. Kagaya Y, Ishide N, Takeyama D, Kanno Y, Yamane Y, Shirato K, et al. Differences in myocardial fluoro-18 2-deoxyglucose uptake in young versus older patients with hypertrophic cardiomyopathy. Am J Cardiol 1992;69:242-6.
146. Nienaber CA, Gambhir SS, Vaghaiwalla Mody F, Ratib O, Huang SC, Phelps ME, et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation 1993;87:1580-90.
147. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
148. Posma JL, Blanksma PK, van der Wall EE. Redistribution of myocardial perfusion during permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy: a quantitative positron emission tomography study. Heart 1996;75:522-4.